Cardiac arrhythmia diagnosis and treatment specialist Biosense has launched CARTO 3 System Version 8, a 3D heart mapping system used in cardiac ablation procedures.
This latest version introduces new modules aimed at enhancing the reproducibility, efficiency and accuracy of catheter ablation procedures for treating atrial fibrillation (AFib) and other arrhythmias.
The software’s modules include the CARTO ELEVATE Module and the CARTOSOUND FAM Module.
Using the US Food and Drug Administration (FDA)-cleared AI algorithm, the CARTOSOUND FAM Module allows automatic generation of the left atrial anatomy before catheter insertion, offering time savings and high accuracy.
The module uses deep-learning technology, a subset of AI, to deliver automated 3D shell creation.
The CARTO ELEVATE Module incorporates several new features including the OPTRELL Mapping Catheter for localised unipolar signals, as well as complex signals identification for pinpointing areas of interest.
It also features pattern acquisition to automatically monitor arrhythmia burden and an enhanced CONFIDENSE Module for optimised mapping.
Biosense Webster president Jasmina Brooks said: “We are pleased to announce this new version of our CARTO 3 System, which reflects our continued focus on harnessing the latest science and technology to advance tools for electrophysiologists to treat cardiac arrhythmias.
“The CARTO 3 System has been the cornerstone of catheter ablation procedures for more than a decade, helping electrophysiologists make treatment decisions.
“This new version advances the CARTO 3 mapping and ablation experience through enhanced signal analysis, improved substrate characterization, and utilisation of ultrasound technology.”
Initially launched in 2009, the CARTO 3 System employs electromagnetic technology to create real-time, 3D maps of a patient's cardiac structures.
The Version 8 update also brings significant advancements, such as the OPTRELL Mapping Catheter with MULTIPOLAR technology for improved signal quality.
In March 2024, Biosense Webster filed a premarket approval application with the FDA for its VARIPULSE Platform, designed to treat paroxysmal atrial fibrillation.
